Published in Magn Reson Imaging on February 18, 2010
A large volume double channel 1H-X RF probe for hyperpolarized magnetic resonance at 0.0475 T. J Magn Reson (2012) 1.29
NMR hyperpolarization techniques for biomedicine. Chemistry (2014) 1.21
Fast volumetric imaging of ethanol metabolism in rat liver with hyperpolarized [1-(13) C]pyruvate. NMR Biomed (2012) 1.03
(15)N Hyperpolarization by Reversible Exchange Using SABRE-SHEATH. J Phys Chem C Nanomater Interfaces (2015) 1.01
A hyperpolarized equilibrium for magnetic resonance. Nat Commun (2013) 0.91
Dynamic metabolic imaging of hyperpolarized [2-(13) C]pyruvate using spiral chemical shift imaging with alternating spectral band excitation. Magn Reson Med (2013) 0.87
Molecular imaging with endogenous substances. Proc Natl Acad Sci U S A (2003) 6.90
Multicoil Dixon chemical species separation with an iterative least-squares estimation method. Magn Reson Med (2004) 4.88
Parahydrogen-induced polarization in imaging: subsecond (13)C angiography. Magn Reson Med (2001) 4.85
In vivo 13 carbon metabolic imaging at 3T with hyperpolarized 13C-1-pyruvate. Magn Reson Med (2007) 3.58
Ultra-fast three dimensional imaging of hyperpolarized 13C in vivo. MAGMA (2005) 2.17
Spatial mapping of the chemical shift in NMR. Magn Reson Med (1984) 2.13
Clinical experience with 13C MRS in vivo. NMR Biomed (2003) 1.95
NMR determination of the TCA cycle rate and alpha-ketoglutarate/glutamate exchange rate in rat brain. J Cereb Blood Flow Metab (1992) 1.89
Optimization of fast spiral chemical shift imaging using least squares reconstruction: application for hyperpolarized (13)C metabolic imaging. Magn Reson Med (2007) 1.61
Least-squares chemical shift separation for (13)C metabolic imaging. J Magn Reson Imaging (2007) 1.59
Effect of deep pentobarbital anesthesia on neurotransmitter metabolism in vivo: on the correlation of total glucose consumption with glutamatergic action. J Cereb Blood Flow Metab (2002) 1.58
Three-dimensional echo-planar MR spectroscopic imaging at short echo times in the human brain. Radiology (1994) 1.44
Quality assurance of PASADENA hyperpolarization for 13C biomolecules. MAGMA (2008) 1.41
Generalized k-space decomposition with chemical shift correction for non-Cartesian water-fat imaging. Magn Reson Med (2008) 1.34
Water-fat separation with bipolar multiecho sequences. Magn Reson Med (2008) 1.22
Articular cartilage of the knee: rapid three-dimensional MR imaging at 3.0 T with IDEAL balanced steady-state free precession--initial experience. Radiology (2006) 1.11
Two-compartment model for determination of glycolytic rates of solid tumors by in vivo 13C NMR spectroscopy. NMR Biomed (1998) 1.11
High-frequency dynamic nuclear polarization in the nuclear rotating frame. J Magn Reson (2000) 1.11
Glycolysis and glucose transporter 1 as markers of response to hormonal therapy in breast cancer. Int J Cancer (2003) 1.00
Non-invasive measurements of myocardial carbon metabolism using in vivo 13C NMR spectroscopy. NMR Biomed (2002) 1.00
Chemical shift-induced amplitude modulations in images obtained with gradient refocusing. Magn Reson Imaging (1987) 0.92
Effect of changing tumor oxygenation on glycolytic metabolism in a murine C3H mammary carcinoma assessed by in vivo nuclear magnetic resonance spectroscopy. Cancer Res (2001) 0.85
Multinuclear NMR study of the metabolism of drug-sensitive and drug-resistant human breast cancer cells. Ann N Y Acad Sci (1987) 0.84
A method for correctly setting the rf flip angle. Magn Reson Med (1989) 0.82
Fast chemical shift mapping with multiecho balanced SSFP. MAGMA (2006) 0.79
Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia (2009) 7.44
Analysis of cancer metabolism by imaging hyperpolarized nuclei: prospects for translation to clinical research. Neoplasia (2011) 5.53
Functional diffusion map: a noninvasive MRI biomarker for early stratification of clinical brain tumor response. Proc Natl Acad Sci U S A (2005) 4.63
Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma. Proc Natl Acad Sci U S A (2005) 3.15
Iron oxide nanoparticles as a drug delivery vehicle for MRI monitored magnetic targeting of brain tumors. Biomaterials (2007) 3.12
Computed tomography-based biomarker provides unique signature for diagnosis of COPD phenotypes and disease progression. Nat Med (2012) 2.95
Parametric response map as an imaging biomarker to distinguish progression from pseudoprogression in high-grade glioma. J Clin Oncol (2010) 2.90
Functional diffusion map as an early imaging biomarker for high-grade glioma: correlation with conventional radiologic response and overall survival. J Clin Oncol (2008) 2.84
It's not just about anatomy: in vivo bioluminescence imaging as an eyepiece into biology. J Magn Reson Imaging (2002) 2.58
Towards hyperpolarized (13)C-succinate imaging of brain cancer. J Magn Reson (2007) 2.57
Vascular targeted nanoparticles for imaging and treatment of brain tumors. Clin Cancer Res (2006) 2.46
Diffusion magnetic resonance imaging: a biomarker for treatment response in oncology. J Clin Oncol (2007) 2.39
The parametric response map is an imaging biomarker for early cancer treatment outcome. Nat Med (2009) 2.32
The functional diffusion map: an imaging biomarker for the early prediction of cancer treatment outcome. Neoplasia (2006) 2.30
PASADENA hyperpolarization of succinic acid for MRI and NMR spectroscopy. J Am Chem Soc (2008) 2.27
A feasibility study of parametric response map analysis of diffusion-weighted magnetic resonance imaging scans of head and neck cancer patients for providing early detection of therapeutic efficacy. Transl Oncol (2009) 2.10
Clinical experience with 13C MRS in vivo. NMR Biomed (2003) 1.95
Noninvasive real-time imaging of apoptosis. Proc Natl Acad Sci U S A (2002) 1.93
Predicting and monitoring cancer treatment response with diffusion-weighted MRI. J Magn Reson Imaging (2010) 1.82
The molecular basis for gray and white matter contrast in phase imaging. Neuroimage (2008) 1.80
Survival prediction in high-grade gliomas by MRI perfusion before and during early stage of RT [corrected]. Int J Radiat Oncol Biol Phys (2005) 1.79
Sp1 and Sp3 are oxidative stress-inducible, antideath transcription factors in cortical neurons. J Neurosci (2003) 1.72
Molecular imaging of Akt kinase activity. Nat Med (2007) 1.68
Brain cancer diagnosis and therapy with nanoplatforms. Adv Drug Deliv Rev (2006) 1.66
A methodology for registration of a histological slide and in vivo MRI volume based on optimizing mutual information. Mol Imaging (2006) 1.63
Multi-system repeatability and reproducibility of apparent diffusion coefficient measurement using an ice-water phantom. J Magn Reson Imaging (2012) 1.57
PASADENA hyperpolarization of 13C biomolecules: equipment design and installation. MAGMA (2008) 1.56
Hyperpolarized water as an MR imaging contrast agent: feasibility of in vivo imaging in a rat model. Radiology (2012) 1.54
Clinical proton MR spectroscopy in central nervous system disorders. Radiology (2014) 1.53
Diffusion MRI: a new strategy for assessment of cancer therapeutic efficacy. Mol Imaging (2002) 1.53
A feasibility study evaluating the functional diffusion map as a predictive imaging biomarker for detection of treatment response in a patient with metastatic prostate cancer to the bone. Neoplasia (2007) 1.50
Diffusion coefficient measurement using a temperature-controlled fluid for quality control in multicenter studies. J Magn Reson Imaging (2011) 1.50
Magnetic resonance imaging determination of tumor grade and early response to temozolomide in a genetically engineered mouse model of glioma. Clin Cancer Res (2007) 1.48
Phosphorylated FADD induces NF-kappaB, perturbs cell cycle, and is associated with poor outcome in lung adenocarcinomas. Proc Natl Acad Sci U S A (2005) 1.44
Therapeutic efficacy of DTI-015 using diffusion magnetic resonance imaging as an early surrogate marker. Clin Cancer Res (2004) 1.42
Quality assurance of PASADENA hyperpolarization for 13C biomolecules. MAGMA (2008) 1.41
Prospective analysis of parametric response map-derived MRI biomarkers: identification of early and distinct glioma response patterns not predicted by standard radiographic assessment. Clin Cancer Res (2011) 1.39
Radiation-induced changes in normal-appearing white matter in patients with cerebral tumors: a diffusion tensor imaging study. Int J Radiat Oncol Biol Phys (2008) 1.39
Diffusion imaging for therapy response assessment of brain tumor. Neuroimaging Clin N Am (2009) 1.38
Real-time molecular imaging of tricarboxylic acid cycle metabolism in vivo by hyperpolarized 1-(13)C diethyl succinate. J Am Chem Soc (2011) 1.36
Real-time evaluation of p53 oscillatory behavior in vivo using bioluminescent imaging. Cancer Res (2006) 1.34
Prospective early response imaging biomarker for neoadjuvant breast cancer chemotherapy. Clin Cancer Res (2007) 1.31
Parahydrogen-induced polarization (PHIP) hyperpolarized MR receptor imaging in vivo: a pilot study of 13C imaging of atheroma in mice. NMR Biomed (2011) 1.27
Reduced glutamate neurotransmission in patients with Alzheimer's disease -- an in vivo (13)C magnetic resonance spectroscopy study. MAGMA (2003) 1.26
An imaging biomarker of early treatment response in prostate cancer that has metastasized to the bone. Cancer Res (2007) 1.26
A small-molecule furin inhibitor inhibits cancer cell motility and invasiveness. Neoplasia (2008) 1.25
The use of 19F spectroscopy and diffusion-weighted MRI to evaluate differences in gene-dependent enzyme prodrug therapies. Mol Ther (2004) 1.25
A novel polyacrylamide magnetic nanoparticle contrast agent for molecular imaging using MRI. Mol Imaging (2003) 1.25
Hyperpolarized (1)H NMR employing low gamma nucleus for spin polarization storage. J Am Chem Soc (2009) 1.24
Dynamic imaging of emerging resistance during cancer therapy. Cancer Res (2006) 1.23
Efficacy of proton magnetic resonance spectroscopy in neurological diagnosis and neurotherapeutic decision making. NeuroRx (2005) 1.23
Noninvasive imaging of apoptosis and its application in cancer therapeutics. Clin Cancer Res (2008) 1.21
Inhibition of furin/proprotein convertase-catalyzed surface and intracellular processing by small molecules. J Biol Chem (2009) 1.20
Noninvasive molecular imaging sheds light on the synergy between 5-fluorouracil and TRAIL/Apo2L for cancer therapy. Clin Cancer Res (2007) 1.16
The extent and severity of vascular leakage as evidence of tumor aggressiveness in high-grade gliomas. Cancer Res (2006) 1.15
Diffusion imaging: insight to cell status and cytoarchitecture. Neuroimaging Clin N Am (2006) 1.15
Skeletal muscle oxidative metabolism in sedentary humans: 31P-MRS assessment of O2 supply and demand limitations. J Appl Physiol (1985) (2004) 1.15
Voxel-by-voxel functional diffusion mapping for early evaluation of breast cancer treatment. Inf Process Med Imaging (2009) 1.15
Perifosine and CCI 779 co-operate to induce cell death and decrease proliferation in PTEN-intact and PTEN-deficient PDGF-driven murine glioblastoma. PLoS One (2011) 1.12
Molecular imaging of N-linked glycosylation suggests glycan biosynthesis is a novel target for cancer therapy. Clin Cancer Res (2010) 1.10
Molecular imaging of gene expression and efficacy following adenoviral-mediated brain tumor gene therapy. Mol Imaging (2003) 1.10
Clinical appraisal of chronic traumatic encephalopathy: current perspectives and future directions. Curr Opin Neurol (2011) 1.10
Diffusion magnetic resonance imaging: an imaging treatment response biomarker to chemoradiotherapy in a mouse model of squamous cell cancer of the head and neck. Transl Oncol (2008) 1.09
Systematic investigation of balanced steady-state free precession for functional MRI in the human visual cortex at 3 Tesla. Magn Reson Med (2007) 1.08
Dental MRI: imaging of soft and solid components without ionizing radiation. J Magn Reson Imaging (2012) 1.08
Cardiovascular applications of hyperpolarized contrast media and metabolic tracers. Exp Biol Med (Maywood) (2009) 1.06
Cotargeting MAPK and PI3K signaling with concurrent radiotherapy as a strategy for the treatment of pancreatic cancer. Mol Cancer Ther (2012) 1.06
Sodium magnetic resonance imaging of chemotherapeutic response in a rat glioma. Magn Reson Med (2005) 1.01
Nuclear localized phosphorylated FADD induces cell proliferation and is associated with aggressive lung cancer. Cell Cycle (2005) 1.01
A continuous-flow, high-throughput, high-pressure parahydrogen converter for hyperpolarization in a clinical setting. NMR Biomed (2012) 1.00
Fluorine-19 NMR chemical shift probes molecular binding to lipid membranes. J Phys Chem B (2008) 1.00
Intravoxel water diffusion heterogeneity imaging of human high-grade gliomas. NMR Biomed (2010) 1.00
Sodium and proton diffusion MRI as biomarkers for early therapeutic response in subcutaneous tumors. Magn Reson Imaging (2006) 0.99
Comparison of apparent diffusion coefficients and distributed diffusion coefficients in high-grade gliomas. J Magn Reson Imaging (2010) 0.99
Clinical NOE 13C MRS for neuropsychiatric disorders of the frontal lobe. J Magn Reson (2008) 0.99
In vivo characterization of fatty acids in human adipose tissue using natural abundance 1H decoupled 13C MRS at 1.5 T: clinical applications to dietary therapy. NMR Biomed (2003) 0.99
Development of a syngeneic rat brain tumor model expressing EGFRvIII and its use for molecular targeting studies with monoclonal antibody L8A4. Clin Cancer Res (2005) 0.99
Identification of inhibitors using a cell-based assay for monitoring Golgi-resident protease activity. Anal Biochem (2007) 0.98
Continuous flow Overhauser dynamic nuclear polarization of water in the fringe field of a clinical magnetic resonance imaging system for authentic image contrast. J Magn Reson (2010) 0.98
Analysis and correction of gradient nonlinearity bias in apparent diffusion coefficient measurements. Magn Reson Med (2014) 0.98
Continuous arterial spin labeling using a train of adiabatic inversion pulses. J Magn Reson Imaging (2005) 0.98
Proton and sodium MRI assessment of emerging tumor chemotherapeutic resistance. NMR Biomed (2006) 0.97
Glial dysfunction in abstinent methamphetamine abusers. J Cereb Blood Flow Metab (2009) 0.97